BIIB - Comparing Biogen With Industry Competitors In Biotechnology Industry | Benzinga
In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Biogen (NASDAQ:BIIB) and its primary competitors in the Biotechnology industry. By closely examining key financial metrics, market position, and growth prospects, our aim is to provide valuable insights for investors and shed light on company's performance within the industry.
Biogen Background
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| Biogen Inc | |||||||
| 25.44 | |||||||
| 2.56 | |||||||
| 3.73 | |||||||
| -0.47% | |||||||
| $0.05 | |||||||
| $1.87 | |||||||
| 0.87% | |||||||
| AbbVie Inc | |||||||
| 44.47 | |||||||
| 23.69 | |||||||
| 5.22 | |||||||
| 14.25% | |||||||
| $4.74 | |||||||
| $7.44 | |||||||
| -5.97% | |||||||
| Amgen Inc | |||||||
| 21.85 | |||||||
| 21.48 | |||||||
| 6.16 | |||||||
| 23.97% | |||||||
| $3.6 | |||||||
| $5.1 | |||||||
| 3.77% | |||||||
| Vertex Pharmaceuticals Inc | |||||||
| 31.61 | |||||||
| 6.57 | |||||||
| 11.35 | |||||||
| 6.47% | |||||||
| $1.23 | |||||||
| $2.16 | |||||||
| 6.39% | |||||||
| Gilead Sciences Inc | |||||||
| 18.43 | |||||||
| 4.81 | |||||||
| 3.96 | |||||||
| 10.03% | |||||||
| $3.23 | |||||||
| $5.49 | |||||||
| 0.11% | |||||||
| Regeneron Pharmaceuticals Inc | |||||||
| 25.74 | |||||||
| 3.95 | |||||||
| 7.84 | |||||||
| 4.12% | |||||||
| $1.23 | |||||||
| $2.93 | |||||||
| 14.53% | |||||||
| BioNTech SE | |||||||
| 8.81 | |||||||
| 1.19 | |||||||
| 3.63 | |||||||
| 0.81% | |||||||
| $0.27 | |||||||
| $0.24 | |||||||
| -74.13% | |||||||
| Genmab A/S | |||||||
| 33.85 | |||||||
| 4.63 | |||||||
| 8.54 | |||||||
| 7.11% | |||||||
| $2.71 | |||||||
| $4.64 | |||||||
| 16.08% | |||||||
| Biomarin Pharmaceutical Inc | |||||||
| 124.87 | |||||||
| 3.70 | |||||||
| 7.95 | |||||||
| 0.83% | |||||||
| $0.07 | |||||||
| $0.46 | |||||||
| 15.04% | |||||||
| Incyte Corp | |||||||
| 34.24 | |||||||
| 2.93 | |||||||
| 4.02 | |||||||
| 3.54% | |||||||
| $0.26 | |||||||
| $0.86 | |||||||
| 11.63% | |||||||
| Neurocrine Biosciences Inc | |||||||
| 70.37 | |||||||
| 6.56 | |||||||
| 7.54 | |||||||
| 4.31% | |||||||
| $0.12 | |||||||
| $0.49 | |||||||
| 28.59% | |||||||
| United Therapeutics Corp | |||||||
| 12.36 | |||||||
| 1.84 | |||||||
| 5.04 | |||||||
| 4.81% | |||||||
| $0.38 | |||||||
| $0.54 | |||||||
| 18.1% | |||||||
| Average | |||||||
| 38.78 | |||||||
| 7.4 | |||||||
| 6.48 | |||||||
| 7.3% | |||||||
| $1.62 | |||||||
| $2.76 | |||||||
| 3.1% |